Trials / Completed
CompletedNCT05354453
A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0001)
Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 1839100 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This trial starts the clinical development of BI 1839100. Effects of single rising doses of BI 1389100 on safety, tolerability and pharmacokinetics will be assessed as basis for further development in patients with pulmonary fibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1839100 | BI 1839100 |
| DRUG | Placebo | Placebo |
| DRUG | allyl isothiocyanate (AITC) | allyl isothiocyanate (AITC) |
Timeline
- Start date
- 2022-05-23
- Primary completion
- 2023-06-14
- Completion
- 2023-06-14
- First posted
- 2022-04-29
- Last updated
- 2023-07-03
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT05354453. Inclusion in this directory is not an endorsement.